Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Congenica Ltd. is currently managing a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 2 pending office actions, indicating the current level of active prosecution. These actions are being handled by 2 distinct examiners, which suggests that the company is interacting with multiple officials at the USPTO. One of these examiners is PLAYER, ROBERT AUSTIN, who is identified as the busiest examiner for the portfolio. With 1 busiest examiner pending action assigned to this individual, the workload is distributed across the 2 distinct examiners.
The prosecution activity is concentrated within 1 distinct art unit, even though multiple examiners are involved. This indicates that while the company's innovations are reviewed by different people, they all fall under the same administrative and technical classification. Operating within 1 distinct art unit allows the company to focus on a single set of procedural standards and supervisory guidelines. The presence of 2 pending office actions requires the company to manage multiple responses. Because there are 2 distinct examiners involved, the company must be prepared for potentially different examination styles within the same art unit. This 1 busiest examiner pending action represents a portion of the current active workload for Congenica Ltd.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PLAYER, ROBERT AUSTIN | 1 | 14.3% | +33.8% |
| DHARITHREESAN, NIDHI | 1 | 39.6% | +36.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17792535 | SCREENING SYSTEM AND METHOD FOR ACQUIRING AND PROCESSING GENOMIC INFORMATION FOR GENERATING GENE VARIANT INTERPRETATIONS | PLAYER, ROBERT AUSTIN | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17792535 | SCREENING SYSTEM AND METHOD FOR ACQUIRING AND PROCESSING GENOMIC INFORMATION FOR GENERATING GENE VARIANT INTERPRETATIONS | PLAYER, ROBERT AUSTIN | 13d |
| 17628827 | SYSTEM AND METHOD FOR COPY NUMBER VARIANT ERROR CORRECTION | DHARITHREESAN, NIDHI | — |
| Art Unit | Apps |
|---|---|
| 1686 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17792535 | SCREENING SYSTEM AND METHOD FOR ACQUIRING AND PROCESSING GENOMIC INFORMATION FOR GENERATING GENE VARIANT INTERPRETATIONS | PLAYER, ROBERT AUSTIN | 1686 | §101§103§112 | Final Rejection | 13d | Pending | Jul 13, 2022 |
| 17628827 | SYSTEM AND METHOD FOR COPY NUMBER VARIANT ERROR CORRECTION | DHARITHREESAN, NIDHI | 1686 | — | Final Rejection | — | Pending | Jan 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial